These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 25666449)

  • 1. Therapeutic development in amyotrophic lateral sclerosis.
    Bucchia M; Ramirez A; Parente V; Simone C; Nizzardo M; Magri F; Dametti S; Corti S
    Clin Ther; 2015 Mar; 37(3):668-80. PubMed ID: 25666449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC; Vucic S; Krishnan AV; Kiernan MC
    Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
    Goyal NA; Mozaffar T
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.
    Talman P; Duong T; Vucic S; Mathers S; Venkatesh S; Henderson R; Rowe D; Schultz D; Edis R; Needham M; Macdonnell R; McCombe P; Birks C; Kiernan M
    BMJ Open; 2016 Sep; 6(9):e012054. PubMed ID: 27694488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis: clinical management and research update.
    Andrews J
    Curr Neurol Neurosci Rep; 2009 Jan; 9(1):59-68. PubMed ID: 19080755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives.
    Ralli M; Lambiase A; Artico M; de Vincentiis M; Greco A
    Isr Med Assoc J; 2019 Jul; 21(7):438-443. PubMed ID: 31507117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapy options for amyotrophic lateral sclerosis.
    Gordon P; Corcia P; Meininger V
    Expert Opin Pharmacother; 2013 Oct; 14(14):1907-17. PubMed ID: 23855817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in motor neuron disease.
    Van Damme P; Robberecht W
    Curr Opin Neurol; 2009 Oct; 22(5):486-92. PubMed ID: 19593125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic news in ALS.
    Corcia P; Beltran S; Bakkouche SE; Couratier P
    Rev Neurol (Paris); 2021 May; 177(5):544-549. PubMed ID: 33781562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in clinical trials for amyotrophic lateral sclerosis.
    Gordon PH
    Curr Neurol Neurosci Rep; 2005 Feb; 5(1):48-54. PubMed ID: 15676108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.
    Kumar V; Islam A; Hassan MI; Ahmad F
    Eur J Med Chem; 2016 Oct; 121():903-917. PubMed ID: 27372371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
    Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motoneuron Disease: Clinical.
    Ilieva H; Maragakis NJ
    Adv Neurobiol; 2017; 15():191-210. PubMed ID: 28674982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in ALS: an overview.
    Turner MR; Parton MJ; Leigh PN
    Semin Neurol; 2001 Jun; 21(2):167-75. PubMed ID: 11442325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.
    Georgoulopoulou E; Fini N; Vinceti M; Monelli M; Vacondio P; Bianconi G; Sola P; Nichelli P; Mandrioli J
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):338-45. PubMed ID: 23373475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of stem cells therapy in amyotrophic lateral sclerosis.
    Je G; Keyhanian K; Ghasemi M
    Neurol Res; 2021 Aug; 43(8):616-632. PubMed ID: 33632084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.